139 related articles for article (PubMed ID: 24670341)
1. Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab - case report.
Dilling P; Walczak J; Pikiel P; Kruszewski WJ
Pol Przegl Chir; 2014 Feb; 86(2):94-6. PubMed ID: 24670341
[TBL] [Abstract][Full Text] [Related]
2. Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib.
Frieling T; Heise J; Wassilew SW
Dtsch Med Wochenschr; 2009 Jul; 134(28-29):e1-2, 1464-6. PubMed ID: 19572243
[TBL] [Abstract][Full Text] [Related]
3. Sigmoid diverticulosis--a risk factor for perforation of the sigmoid colon due to ipilimumab-associated enterocolitis?
Hrgovic I; Winkelmann R; Vogl TJ; von Wagner M; El Youzouri H; Kaufmann R; Meissner M
J Dtsch Dermatol Ges; 2015 Jun; 13(6):575-7. PubMed ID: 26018375
[No Abstract] [Full Text] [Related]
4. Ipilimumab-induced colitis in patients with metastatic melanoma.
De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN
Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab-induced acute severe colitis treated by infliximab.
Pagès C; Gornet JM; Monsel G; Allez M; Bertheau P; Bagot M; Lebbé C; Viguier M
Melanoma Res; 2013 Jun; 23(3):227-30. PubMed ID: 23458760
[TBL] [Abstract][Full Text] [Related]
6. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
Woźniak S; Mackiewicz-Wysocka M; Krokowicz Ł; Kwinta Ł; Mackiewicz J
Oncol Res Treat; 2015; 38(3):105-8. PubMed ID: 25792081
[TBL] [Abstract][Full Text] [Related]
7. Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review.
Kopecký J; Trojanová P; Kubeček O; Kopecký O
Jpn J Clin Oncol; 2015 Apr; 45(4):381-4. PubMed ID: 25583422
[TBL] [Abstract][Full Text] [Related]
8. [Surgical management of bevacizumab-associated peritonitis due to perforation].
Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
[TBL] [Abstract][Full Text] [Related]
9. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
Heinzerling JH; Huerta S
Curr Surg; 2006; 63(5):334-7. PubMed ID: 16971205
[TBL] [Abstract][Full Text] [Related]
10. A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.
Gaudy-Marqueste C; Monestier S; Franques J; Cantais E; Richard MA; Grob JJ
J Immunother; 2013 Jan; 36(1):77-8. PubMed ID: 23211620
[TBL] [Abstract][Full Text] [Related]
11. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy.
Pintova S; Sidhu H; Friedlander PA; Holcombe RF
Melanoma Res; 2013 Dec; 23(6):498-501. PubMed ID: 24113862
[TBL] [Abstract][Full Text] [Related]
12. Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma.
Roth ME; Muluneh B; Jensen BC; Madamanchi C; Lee CB
Am J Ther; 2016; 23(6):e1925-e1928. PubMed ID: 26885708
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?
Dick J; Enk A; Hassel JC
Dermatology; 2015; 230(1):8-10. PubMed ID: 25531526
[TBL] [Abstract][Full Text] [Related]
14. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment.
Murphy KP; Kennedy MP; Barry JE; O'Regan KN; Power DG
Oncol Res Treat; 2014; 37(6):351-3. PubMed ID: 24903767
[TBL] [Abstract][Full Text] [Related]
15. Nursing management of patients with metastatic melanoma receiving ipilimumab.
Bryce J; Passoni C
Oncol Nurs Forum; 2013 May; 40(3):215-8. PubMed ID: 23615135
[No Abstract] [Full Text] [Related]
16. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab (Yervoy) and inoperable or metastatic melanoma. More evaluation needed, in both first- and second-line use.
Prescrire Int; 2015 Apr; 24(159):96. PubMed ID: 25941700
[No Abstract] [Full Text] [Related]
18. Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital.
Rastogi P; Sultan M; Charabaty AJ; Atkins MB; Mattar MC
World J Gastroenterol; 2015 Apr; 21(14):4373-8. PubMed ID: 25892889
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
20. Enterocolitis in a patient being treated with ipilimumab for metastatic melanoma.
Koch C; Paetzold S; Trojan J
Gastroenterology; 2012 Aug; 143(2):298, 504, 505. PubMed ID: 22709738
[No Abstract] [Full Text] [Related]
[Next] [New Search]
